Skip to main content

Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Phase 1/2 Study To Evaluate RTx-021 in Patients with Stargardt Disease

Other
Baruch Kuppermann
Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients with Stargardt Disease (AURORA)
Other

Study Description

This Phase 1/2, open-label, non-randomized, sequential assignment, first-in-human dose-escalation study is to evaluate the safety and preliminary efficacy of a single, uniocular intravitreal injection of an investigational optogenetic gene therapy, RTx-021, in patients with Stargardt Disease. Up to 3 dose cohorts of RTx-021 are planned, and each cohort will consist initially of 3 patients. The study is a traditional dose escalation design with the potential for cohort expansion and is intended to support dose selection for further clinical development. Patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years with visits being more frequent in the initial 12 months after treatment.

Eligibility

Male and female patients >= 16 years of age

Able to comply with the study visit schedule and all protocol assessments

Diagnosis of Stargardt Disease (genetic testing required)

Study eye and fellow eye Best Corrected Visual Acuity meeting study criteria

Presence of retinal ganglion cells and/or retinal nerve fiber layer on Spectral Domain

Optical Coherence Tomography testing at Screening confirmed by central image reading center

Adequate organ function and general good health

Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent, or therapy in the past six months

Concurrent participation in another interventional clinical ocular study

Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy

Pre-existing eye conditions in either eye that would preclude the planned treatment or are significant enough to interfere with the interpretation of study endpoints or procedural complications

Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications

Complicating systemic diseases including those in which the disease itself, or the treatment of the disease, can alter ocular and/or central nervous system function (e.g. radiation treatment of the orbit; leukemia with optic nerve involvement)

Any immunological response dysfunction including, immuno-compromising diseases or use of immunosuppressive medications, among others

Cataract or other ocular (including refractive) surgery, intraocular and/or peri-ocular injection in either eye within the prior four months (i.e. 120 days) prior to screening

Prior vitrectomy or aphakia in the study eye

Known sensitivity to any component of the study treatment or contraindication to medications planned for use in the peri-procedural period (e.g. povidone-iodine to prep for intravitreal injection)

Known contraindication to prophylactic steroid regimen

Current pregnancy or breastfeeding

Any other condition that would not allow the patient to complete follow-up examinations during the study

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.